IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 13.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,553 shares of the company's stock after purchasing an additional 2,931 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in IDEXX Laboratories were worth $10,731,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. D.A. Davidson & CO. increased its position in IDEXX Laboratories by 2.8% during the fourth quarter. D.A. Davidson & CO. now owns 1,674 shares of the company's stock worth $692,000 after buying an additional 45 shares during the period. Concurrent Investment Advisors LLC increased its holdings in shares of IDEXX Laboratories by 36.7% in the 4th quarter. Concurrent Investment Advisors LLC now owns 861 shares of the company's stock valued at $356,000 after acquiring an additional 231 shares during the period. Olympiad Research LP purchased a new stake in IDEXX Laboratories in the 4th quarter valued at $209,000. Howard Capital Management Inc. raised its position in IDEXX Laboratories by 3.0% in the 4th quarter. Howard Capital Management Inc. now owns 2,304 shares of the company's stock valued at $953,000 after purchasing an additional 67 shares during the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in IDEXX Laboratories by 13.5% during the 4th quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 20,992 shares of the company's stock worth $8,679,000 after purchasing an additional 2,500 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $524.65 on Tuesday. The firm has a 50-day moving average price of $489.21 and a two-hundred day moving average price of $448.49. The company has a market capitalization of $42.19 billion, a P/E ratio of 48.49, a price-to-earnings-growth ratio of 3.83 and a beta of 1.55. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $530.73. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business's revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the business earned $2.71 earnings per share. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on IDXX shares. Stifel Nicolaus upped their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Finally, Leerink Partners boosted their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $546.00.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director now owns 1,801 shares of the company's stock, valued at $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.